DDD2 is a selective and potent VHL-mediated PROTAC NUDT5 degrader. DDD2 induces robust NUDT5 degradation. DDD2 can be used in cancer research, such as lymphocytic leukemia and osteosarcoma[1]. (Structure Note: Pink: NUDT5 inhibitor (HY-176262), Blue: E3 (HY-125845), Black: linker (HY-W001958))
Molecular Weight:
1035.22
Formula:
C52H66N12O9S
Target:
PROTACs
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
